Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07336381 · ClinicalTrials.gov registry record · NA
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
A NA study of Peripheral Arterial Disease and Peripheral Neuropathy, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07336381: Recruiting NA study of Peripheral Arterial Disease and Peripheral Neuropathy, sponsored by Indiana University.
NCT07336381 is a NA study of Peripheral Arterial Disease and Peripheral Neuropathy that is actively recruiting participants, run by Indiana University. The registered enrollment target is 10 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07336381, a NA study of Peripheral Arterial Disease and Peripheral Neuropathy, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.
Primary Outcome
Patients will be treated twice daily for three months with the Replexa+ device. Lower extremity arterial dopplers (LEADs) will be assessed at baseline and post-treatment to determine improvement in lower extremity perfusion.
Conditions Studied
Interventions
- DEVICE Replexa shortwave diathermy
Study Locations (1)
Indiana
- Richard L. Roudebush Veterans Affairs Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT07336381 shows while recruiting
NCT07336381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which Replexa shortwave diathermy is the first listed.
NCT07336381 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07336381 about?
NCT07336381 is a clinical study titled "Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy". This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.
What is the current status of trial NCT07336381?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-12-05. Estimated completion is 2026-12-31.
What conditions does trial NCT07336381 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Peripheral Neuropathy.
What interventions are being tested in trial NCT07336381?
The interventions under investigation include: Replexa shortwave diathermy (DEVICE).
Who is sponsoring clinical trial NCT07336381?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07336381 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07336381's enrollment target sits among peer trials
10 76th of 79 higher than 3 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
-
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI